AstraZeneca PLC
AZN: XLON (GBR)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|R#%b | LOCK|Xm | LOCK|>F?$Zm? |
AstraZeneca Earnings: Excellent Growth, Three-Year Restructuring Program To Invest in Pipeline
At constant currencies, Astra’s revenue grew 7% year on year, and core EPS rose 19%. Management reiterated its guidance and announced a three-year restructuring program to reallocate $1.5 billion of annual costs to its pipeline. Shares closed 7% higher on Oct. 30, from the previous day’s close.
